Gyre Therapeutics (GYRE) Competitors $13.12 -0.72 (-5.20%) (As of 11/15/2024 ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends GYRE vs. NUVL, LNTH, ACLX, KRYS, ADMA, RNA, BHVN, BBIO, CRNX, and TGTXShould you be buying Gyre Therapeutics stock or one of its competitors? The main competitors of Gyre Therapeutics include Nuvalent (NUVL), Lantheus (LNTH), Arcellx (ACLX), Krystal Biotech (KRYS), ADMA Biologics (ADMA), Avidity Biosciences (RNA), Biohaven (BHVN), BridgeBio Pharma (BBIO), Crinetics Pharmaceuticals (CRNX), and TG Therapeutics (TGTX). These companies are all part of the "pharmaceutical products" industry. Gyre Therapeutics vs. Nuvalent Lantheus Arcellx Krystal Biotech ADMA Biologics Avidity Biosciences Biohaven BridgeBio Pharma Crinetics Pharmaceuticals TG Therapeutics Nuvalent (NASDAQ:NUVL) and Gyre Therapeutics (NASDAQ:GYRE) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, community ranking, media sentiment, earnings, institutional ownership, analyst recommendations, risk, valuation and profitability. Does the MarketBeat Community favor NUVL or GYRE? Nuvalent received 40 more outperform votes than Gyre Therapeutics when rated by MarketBeat users. CompanyUnderperformOutperformNuvalentOutperform Votes4076.92% Underperform Votes1223.08% Gyre TherapeuticsN/AN/A Do institutionals & insiders believe in NUVL or GYRE? 97.3% of Nuvalent shares are held by institutional investors. Comparatively, 24.0% of Gyre Therapeutics shares are held by institutional investors. 12.5% of Nuvalent shares are held by insiders. Comparatively, 19.5% of Gyre Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Which has higher earnings & valuation, NUVL or GYRE? Gyre Therapeutics has higher revenue and earnings than Nuvalent. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNuvalentN/AN/A-$126.22M-$3.47-25.04Gyre Therapeutics$113.45M10.82-$92.93MN/AN/A Is NUVL or GYRE more profitable? Nuvalent has a net margin of 0.00% compared to Gyre Therapeutics' net margin of -84.57%. Nuvalent's return on equity of -28.63% beat Gyre Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets NuvalentN/A -28.63% -27.15% Gyre Therapeutics -84.57%-118.43%-71.97% Which has more volatility and risk, NUVL or GYRE? Nuvalent has a beta of 1.33, meaning that its share price is 33% more volatile than the S&P 500. Comparatively, Gyre Therapeutics has a beta of 2.05, meaning that its share price is 105% more volatile than the S&P 500. Do analysts rate NUVL or GYRE? Nuvalent currently has a consensus price target of $112.60, indicating a potential upside of 29.60%. Given Nuvalent's stronger consensus rating and higher probable upside, equities research analysts clearly believe Nuvalent is more favorable than Gyre Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nuvalent 1 Sell rating(s) 1 Hold rating(s) 10 Buy rating(s) 1 Strong Buy rating(s) 2.85Gyre Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Does the media prefer NUVL or GYRE? In the previous week, Nuvalent had 15 more articles in the media than Gyre Therapeutics. MarketBeat recorded 22 mentions for Nuvalent and 7 mentions for Gyre Therapeutics. Gyre Therapeutics' average media sentiment score of 0.59 beat Nuvalent's score of 0.24 indicating that Gyre Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nuvalent 5 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Gyre Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive SummaryNuvalent beats Gyre Therapeutics on 10 of the 15 factors compared between the two stocks. Ad Porter & CompanyThis company will win the AI race Rome wasn’t built in a day… But there is another lesser-known type of keystone, one that plays an equally critical role in supporting the most revolutionary technology the world’s ever seen… artificial intelligence. And without it, the entire AI industry would collapse. You must read this new presentation from Porter Stansberry. Get Gyre Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for GYRE and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GYRE vs. The Competition Export to ExcelMetricGyre TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.23B$6.49B$5.13B$8.74BDividend YieldN/A8.15%5.18%4.07%P/E RatioN/A4.8266.7313.27Price / Sales10.82374.171,265.2981.14Price / Cash52.7451.8140.2135.77Price / Book12.509.636.455.92Net Income-$92.93M$154.43M$119.73M$225.73M7 Day Performance-14.36%-9.46%-5.13%-1.34%1 Month Performance-6.42%-7.27%-2.71%1.15%1 Year Performance-10.81%28.13%31.08%24.02% Gyre Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GYREGyre Therapeutics0.5583 of 5 stars$13.12-5.2%N/A+1.2%$1.23B$113.45M0.0040Short Interest ↓News CoverageNUVLNuvalent3.1126 of 5 stars$94.39-1.1%N/A+49.7%$6.12BN/A-33.9540Earnings ReportAnalyst ForecastAnalyst RevisionNews CoverageLNTHLantheus4.6074 of 5 stars$84.08-3.9%N/A+12.7%$5.85B$1.30B13.99834Gap DownHigh Trading VolumeACLXArcellx2.8644 of 5 stars$106.53+3.4%N/A+68.4%$5.73B$144.75M-102.43130Analyst ForecastInsider SellingShort Interest ↓KRYSKrystal Biotech4.7252 of 5 stars$195.87-1.9%N/A+73.6%$5.63B$50.70M110.66229ADMAADMA Biologics3.6392 of 5 stars$22.48-0.6%N/A+399.7%$5.24B$258.21M160.57530Gap UpRNAAvidity Biosciences2.5072 of 5 stars$47.12+0.9%N/A+611.3%$5.17B$9.56M-16.36190Analyst ForecastAnalyst RevisionNews CoverageBHVNBiohaven3.811 of 5 stars$52.41-2.0%N/A+49.6%$4.95B$462.51M-5.73239Earnings ReportAnalyst ForecastNews CoverageBBIOBridgeBio Pharma4.6019 of 5 stars$26.12-3.6%N/A-17.8%$4.91B$9.30M-9.93400Analyst ForecastAnalyst RevisionNews CoverageCRNXCrinetics Pharmaceuticals3.5501 of 5 stars$60.01-1.1%N/A+93.1%$4.80B$4.01M-15.88210Earnings ReportAnalyst ForecastShort Interest ↑Analyst RevisionNews CoverageTGTXTG Therapeutics4.6026 of 5 stars$30.74+6.7%N/A+162.3%$4.76B$233.66M-307.37290Insider SellingGap Up Related Companies and Tools Related Companies Nuvalent Competitors Lantheus Competitors Arcellx Competitors Krystal Biotech Competitors ADMA Biologics Competitors Avidity Biosciences Competitors Biohaven Competitors BridgeBio Pharma Competitors Crinetics Pharmaceuticals Competitors TG Therapeutics Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:GYRE) was last updated on 11/17/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredThere is a little known company that is changing warfareWith geo - political instability around the world investors are flocking to defense contract stocks. There...Reticulate | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Gyre Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Gyre Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free GYRE Stock Alerts